Novartis’ iptacopan gets EMA’s orphan drug designation in IgAN

This article was originally published here

The orphan drug status to iptacopan has been granted by the regulator after a recommendation from the Committee for Orphan Medicinal Products (COMP). Although considered to be a

The post Novartis’ iptacopan gets EMA’s orphan drug designation in IgAN appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply